Brii Biosciences Ltd
HKEX:2137
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
CN |
Brii Biosciences Ltd
HKEX:2137
|
860.7m HKD | 3.6 | ||
US |
Abbvie Inc
NYSE:ABBV
|
274.7B USD | 13 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
159.5B USD | 18 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.5B USD | 23.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.8B USD | 22.3 | ||
AU |
CSL Ltd
ASX:CSL
|
134.5B AUD | 21.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
79.2B USD | 8.4 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
56B USD | -10.7 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -61.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.1B USD | 13.7 | ||
KR |
Celltrion Inc
KRX:068270
|
36.7T KRW | 47.3 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.